Document is current
Any future updates will be listed below
-
Authors
Mameli, Chiara https://orcid.org/0000-0002-6768-3411
Guadagni, Liliana https://orcid.org/0009-0002-3803-4073
Orso, Massimiliano https://orcid.org/0000-0003-0200-1202
Calcaterra, Valeria https://orcid.org/0000-0002-2137-5974
Wasniewska, Malgorzata Gabriela https://orcid.org/0000-0002-8299-2677
Aversa, Tommaso https://orcid.org/0000-0002-1754-6822
Granato, Simona https://orcid.org/0000-0002-3509-1446
Bruschini, Pietro
d’Angela, Daniela https://orcid.org/0000-0003-3409-4757
Spandonaro, Federico https://orcid.org/0000-0003-1388-2850
Polistena, Barbara https://orcid.org/0000-0002-0138-0223
Zuccotti, Gianvincenzo https://orcid.org/0000-0002-2795-9874
-
Funding
Funding for this research was provided by:
Pfizer Italia
- License Information
-
More Information
Article History
Received: 16 December 2023
Accepted: 9 March 2024
First Online: 18 March 2024
Conflict of interest
: M.G.W. is a consultant for Pfizer, Merck, Sandoz and Novonordisk. C.M. has spoken for Pfizer. T.A. has consulted for Pfizer, and Sandoz. B.P. has received payments or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from the following commercial sources: Allergan, Amgen, Astellas, Baxter, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Janssen Cilag, Jazzpharma, Mylan, Nestle´HS, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Servier, Shire, Takeda, Teva; in addition, she received consulting fees from UCB. F.S. has received payments or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from the following commercial sources: Allergan, Amgen, Astellas, Baxter, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Janssen Cilag, Jazzpharma, Mylan, Nestle´HS, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Servier, Shire, Takeda, Teva; in addition, he received consulting fees from Amgen. S.G. and P.B. are employees of Pfizer. C.M., G.Z., V.C., T.A., M.G.W. were paid consultants to Pfizer in connection with the development of this manuscript.
